← Back to Patent Explorer
US4307071A Expired / Lapsed US ⏱️ 0.0 years remaining

Analytical reagent and method

Assignee: SANOFI K Co
•
Filing: 1977-08-02
•
Granted: 1981-12-22
•
Expires: 1997-08-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A reagent is disclosed for determining the concentration of a ligand in blood serum. The reagent includes a protenaceous, three-dimensional, serum-insoluble complex which is readily collected by centrifugation, the complex comprising non-specific immunoglobulins, anti-ligand immunoglobulins, immunoglobulins which are antibodies to the previously mentioned immunoglobulins and which are complexed therewith, and a labeled ligand complexed with the anti-ligand immunoglobulins. The reagent is particularly useful in competitive binding analyses such as radioimmunoassays.

Inventors

  • 👤 Dennis M. Murray
  • 👤 John W. Rosevear
  • 👤 Dan C. Drinkwitz

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 15:37
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/531; G01N33/532; G01N33/74; G01N33/78; Y; Y10; Y10S; Y10S436/00; Y10S436/804; Y10S436/815; Y10S436/817; Y10S530/00; Y10S530/81; Y10S530/812; Y10S530/815; Y10S530/817

Claims Analysis

Total Claims: 21
Claim 1
Independent Claim 64 words
Reagent for determining the concentration of a ligand in human blood serum and including a suspendable, water-insoluble, three-dimensional, proteinaceous complex which includes non-specific immunoglobulins, anti-ligand immunoglobulins, immunoglobulins which are antibodies to both the previously named immunoglobulins and which are complexed therewith to form said three-dimensional complex, and a labeled ligand complexed with the anti-ligand immunoglobulins, the complex being easily removed from suspension through centrifugation.
Claim 2
Dependent Claim 64 words
Reagent for determining the concentration of a ligand in human blood serum and including a suspendable, water-insoluble, three-dimensional, proteinaceous complex which includes non-specific immunoglobulins, anti-ligand immunoglobulins, immunoglobulins which are antibodies to both the previously named immunoglobulins and which are complexed therewith to form said three-dimensional complex, and a labeled ligand complexed with the anti-ligand immunoglobulins, the complex being easily removed from suspension through centrifugation.
Claim 3
Dependent Claim 18 words
The reagent of claim 1 wherein the labeled ligand is 125 I-T 4 or 125 I-T 3 .
Claim 4
Dependent Claim 13 words
The reagent of claim 1 wherein the labeled ligand is isotopically labeled cortisol.
Claim 5
Dependent Claim 17 words
The reagent of claim 1 including labeled ligand in excess of that complexed with the anti-ligand immunoglobulins.
Claim 6
Dependent Claim 42 words
The reagent of claim 2 including an aqueous carrier in which the proteinaceous complex is readily suspended, the carrier having a pH of at least about 8 and including a binding inhibitory agent preventing the binding of the ligand to thyroxine-binding globulin.
Claim 7
Dependent Claim 17 words
The reagent of claim 3 including an aqueous carrier in which the proteinaceous complex is readily suspended.
Claim 8
Dependent Claim 12 words
The reagent of claim 1 wherein the non-specific immunoglobulins are rabbit immunoglobulins.
Claim 9
Dependent Claim 14 words
The reagent of claim 1 wherein the anti-ligand immunoglobulins are anti-T 4 rabbit immunoglobulins.
Claim 10
Dependent Claim 14 words
The reagent of claim 1 wherein the anti-ligand immunoglobulins are anti-T 3 rabbit immunoglobulins.
Claim 11
Dependent Claim 28 words
The reagent of claim 1 wherein the immunoglobulins which are antibodies to the non-specific immunoglobulins and to the anti-ligand immunoglobulins are immunoglobulins raised in goats against rabbit immunoglobulins.
Claim 12
Dependent Claim 104 words
Reagent for determining the concentration of a ligand in human blood serum and including a readily suspendable, water-insoluble, three-dimensional, proteinaceous complex which includes nonspecific immunoglobulins from a given animal species and anti-ligand immunoglobulins raised in the same animal species, immunoglobulins raised in a different animal species and which are antibodies to both the previously named immunoglobulins and are complexed therewith to form said three-dimensional complex, and a labeled ligand complexed with the anti-ligand immunoglobulins, the labeled ligand being readily exchanged with unlabeled ligand so as to permit substantial equilibrium between labeled and unlabeled ligands to be reached within about one hour at 56° C.
Claim 13
Dependent Claim 104 words
Reagent for determining the concentration of a ligand in human blood serum and including a readily suspendable, water-insoluble, three-dimensional, proteinaceous complex which includes nonspecific immunoglobulins from a given animal species and anti-ligand immunoglobulins raised in the same animal species, immunoglobulins raised in a different animal species and which are antibodies to both the previously named immunoglobulins and are complexed therewith to form said three-dimensional complex, and a labeled ligand complexed with the anti-ligand immunoglobulins, the labeled ligand being readily exchanged with unlabeled ligand so as to permit substantial equilibrium between labeled and unlabeled ligands to be reached within about one hour at 56° C.
Claim 14
Dependent Claim 109 words
In the method for the competitive binding assay of a ligand in human blood serum, the steps which comprise combining a measured quantity of human blood serum with a single, aqueous reagent which includes a suspendable, water-insoluble, three-dimensional, proteinaceous complex comprising non-specific immunoglobulins, anti-ligand immunoglobulins, immunoglobulins which are antibodies to both the previously named immunoglobulins and which are complexed therewith to form said three-dimensional complex, and a labeled ligand complexed with the anti-ligand immunoglobulins; and incubating the combined serum and reagent for not greater than about one hour at a temperature up to about 56° C. to permit substantial equilibrium between antibody-bound labeled and unlabeled ligands to be reached.
Claim 15
Dependent Claim 109 words
In the method for the competitive binding assay of a ligand in human blood serum, the steps which comprise combining a measured quantity of human blood serum with a single, aqueous reagent which includes a suspendable, water-insoluble, three-dimensional, proteinaceous complex comprising non-specific immunoglobulins, anti-ligand immunoglobulins, immunoglobulins which are antibodies to both the previously named immunoglobulins and which are complexed therewith to form said three-dimensional complex, and a labeled ligand complexed with the anti-ligand immunoglobulins; and incubating the combined serum and reagent for not greater than about one hour at a temperature up to about 56° C. to permit substantial equilibrium between antibody-bound labeled and unlabeled ligands to be reached.
Claim 16
Dependent Claim 21 words
The method of claim 12 in which the ligand to be assayed is T 4 , T 3 , or cortisol.
Claim 17
Dependent Claim 57 words
The method of claim 13 including the steps of combining predetermined quantities of said reagent with standardized samples containing known concentrations of ligand and preparing a calibration curve in which, following attainment of substantial equilibrium between antibody-bound labeled and unlabeled ligands, values indicative of labeled or unlabeled ligand concentration are plotted against known concentrations of the ligand.
Claim 18
Independent Claim 129 words
A method for preparing a liquid reagent for assaying the concentration of a ligand in human blood serum, comprising; (a) providing immunoglobulins from a first animal species which are anti-ligand antibodies; (b) providing immunoglobulins from a second animal species which are antibodies specific to immunoglobulins from the first animal species; (c) providing non-specific immunoglobulins from the first animal species; (d) reacting the non-specific immunoglobulins and the immunoglobulins from the second animal species to form an insoluble three-dimensional complex; (e) thereafter reacting the immunoglobulins which are anti-ligand antibodies with the complex to provide the complex with a plurality of available ligand binding sites; and (f) thereafter reacting the complex with labeled ligand in sufficient quantity so that a significant fraction of the binding sites are complexed with the labeled ligand.
Claim 19
Independent Claim 129 words
A method for preparing a liquid reagent for assaying the concentration of a ligand in human blood serum, comprising; (a) providing immunoglobulins from a first animal species which are anti-ligand antibodies; (b) providing immunoglobulins from a second animal species which are antibodies specific to immunoglobulins from the first animal species; (c) providing non-specific immunoglobulins from the first animal species; (d) reacting the non-specific immunoglobulins and the immunoglobulins from the second animal species to form an insoluble three-dimensional complex; (e) thereafter reacting the immunoglobulins which are anti-ligand antibodies with the complex to provide the complex with a plurality of available ligand binding sites; and (f) thereafter reacting the complex with labeled ligand in sufficient quantity so that a significant fraction of the binding sites are complexed with the labeled ligand.
Claim 20
Dependent Claim 24 words
The method of claim 15 in which the labeled ligand is provided in a quantity sufficient to provide unbound labeled ligand in the reagent.
Claim 21
Dependent Claim 26 words
The method of claim 15 including the subsequent step of dispensing the reagent into a storage container having walls less transmissive of light than clear glass.

References Cited (Backward Citations)

US2957808A Cited
US3928553A Cited
US3911096A Cited
US3951748A Cited
US3995019A Cited
US4018883A Cited
US4034073A Cited
US4021534A Cited
US4069352A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-12-21 1985-06-22 1985-12-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-12-21 1989-06-22 1989-12-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-12-21 1993-06-22 1993-12-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag